

07-4-603

915-603 5

NITRIC OXIDE

BIOCHEMISTRY, MOLECULAR BIOLOGY,
AND THERAPEUTIC IMPLICATIONS

Volume Editors:

Louis Ignarro

Department of Pharmacology
Center for Health Sciences
UCLA School of Medicine
Los Angeles, California

Ferid Murad

Molecular Geriatrics Corporation
Lake Bluff, Illinois



ACADEMIC PRESS

San Diego New York Boston London Sydney Tokyo Toronto

Contents

Contributors xix

Chemistry of Nitric Oxide: Biologically Relevant Aspects

Jon M. Fukuto

- I. Introduction 1
- II. Physical and Chemical Properties of NO 2
- III. Reaction of NO with Oxygen 4
- IV. Reaction of NO with Superoxide 6
- V. Chemistry of NO-Derived Nitrogen Oxides 7
- VI. Reactions of NO and NO₂ with Thiols 8
- VII. Reaction of NO with Amines 8
- VIII. Reaction of NO with Heme Proteins and Metals 9
- IX. Reaction of NO with Oxyhemoglobin and Oxymyoglobin 11
- X. Summary 13
- References 13

Reactions between Nitric Oxide, Superoxide, and Peroxynitrite: Footprints of Peroxynitrite *in Vivo*

John P. Crow and Joseph S. Beckman

- I. Introduction 17
- II. Target Areas for Reactive Species 19
- III. Reactions of Nitric Oxide and Rationale for Product Analysis *in Vivo* 20

- A. $\cdot\text{NO}_2$, $\cdot\text{NO}_2^-$, and NO_3^- 21
- B. Primary Reactivity of Nitric Oxide 22
- C. Nitric Oxide Reduction, Oxidation, and Mechanisms of Nitrosation 23
- D. Reductive Release of Nitric Oxide from Nitrosothiols 24
- E. Nitric Oxide as a Chain-Terminating Radical 26
- IV. Oxidative Pathology and the Search for Footprints 26
 - A. Evidence for Hydroxyl Radical Reactivity 27
 - B. ONOO^- Reactivity: The Concept of "Radical Ends" 28
 - C. Reaction of Nitric Oxide with ONOO^- 30
 - D. Phenolic Reaction Products of Nitric Oxide, ONOO^- , or Both 32
- V. Phenolic Reaction Products *in Vivo*: Stable and Specific Footprints of ONOO^- 36
 - A. Tyrosine, Nitration, and Nitrosation 36
 - B. Characterization of an Antinitrotyrosine Antibody 37
 - C. Reactivity of Tyrosine: The Free Amino Acid versus the Residue 38
 - D. Immunological Detection of Endogenously Nitrated Proteins 39
 - E. Possible Mechanisms of ONOO^- -Mediated Pathology 39
- References 40

Oxygen Radical–Nitric Oxide Reactions in Vascular Diseases

Bruce A. Freeman, Roger White, Hector Gutierrez, Andrés Paler-Martínez,
Margaret Tarpey, and Homero Rubbo

- I. Introduction 45
- II. Prooxidant versus Tissue-Protective Reactions of $\cdot\text{NO}$ 47
 - A. Cellular Targets of $\cdot\text{NO}$ 47
 - B. $\cdot\text{NO}$ Reaction with O_2^- 48
 - C. $\cdot\text{NO}$ Reaction with Alkoxyl and Peroxyl Radicals 49
 - D. $\cdot\text{NO}$ Reaction with Iron 50
 - E. $\cdot\text{NO}$ Reaction with $\cdot\text{OH}$ Radical and/or *trans* ONOO^- 50
 - F. $\cdot\text{NO}$ Induction of cGMP-Dependent Protective Effects 50
- III. $\cdot\text{NO}$ –Oxygen Radical Interactions in Atherosclerosis 51
 - A. Pathogenesis of Atherosclerosis 51
 - B. Cellular Events Induced by Oxidized LDL 52
 - C. Mechanisms of LDL Oxidation 52
 - D. $\cdot\text{NO}$ Reaction with Oxidized Lipids and LDL 53
 - E. Nitrotyrosine Immunoreactivity 57
 - F. Oxidative Mechanisms Underlying Impaired Vasomotor Responses in Atherosclerosis 57

- III. $\cdot$ NO–Oxygen Radical Interactions in Transplant Vasculopathy and Restenosis 61
- IV. $\cdot$ NO–Oxygen Radical Interactions in Reperfusion Injury 61
- V. Conclusions 63
- References 65

Nitric Oxide Synthases: Gene Structure and Regulation

Yang Wang and Philip A. Marsden

- I. Overview 71
 - A. Isoforms and Nomenclature 71
 - B. Biochemical Function 72
 - C. Genes Encoding the Three Isoforms 73
- II. nNOS 75
 - A. The nNOS Gene 75
 - B. mRNA Diversity 75
 - C. Tissue (Cell Type)-Specific Expression 77
 - D. Genetic Model of nNos Gene Expression 78
- III. iNOS 79
 - A. The iNOS Gene 79
 - B. Transcriptional Regulation: Activation by Cytokines 80
 - C. Posttranscriptional Regulation 81
 - D. The Puzzling Question 81
- IV. ecNOS 81
 - A. The ecNOS Gene 81
 - B. Transcriptional Regulation 82
 - C. Posttranscriptional Regulation: mRNA Stability 84
- V. Summary 84
- References 85

Transcription of the Human Neuronal Nitric Oxide Synthase Gene in the Central Nervous System Is Mediated by Multiple Promoters

Anthony P. Young, Ferid Murad, Harald Vaessin, Jinling Xie, and Terrie K. Rife

- I. Perspective: Relationship of *NOS1* Gene Expression Studies to Other Aspects of Nitric Oxide Biochemistry, Molecular Biology, and Physiology 91
- II. An Interesting Genomic Structure Underpins Expression of *NOS1* in the CNS 94
 - A. Isolation and Characterization of Human *NOS1* cDNA Clones with Different 5' Untranslated Regions 94

Control and Consequences of Endothelial Nitric Oxide Formation

Ingrid Fleming and Rudi Busse

- I. Endothelial Nitric Oxide Synthase 187
- II. Regulation of Endothelium-Derived Nitric Oxide Formation 188
- III. Shear Stress-Dependent Endothelial NO Release 189
- IV. NOS Regulation at the Transcriptional Level 192
 - A. Shear Stress 192
 - B. Cytokines 193
 - C. Sex Hormones 194
- V. Functional Consequences of Endothelial NO Formation 195
- VI. Effect of NO on Protein Expression and Gene Transcription 196
 - A. P-Selectin 197
 - B. MCP-1 198
- VII. Summary 200
- References 201

Control of Electron Transfer in Neuronal Nitric Oxide Synthase by Calmodulin, Substrate, Substrate Analogs, and Nitric Oxide

Dennis J. Stuehr, Husam M. Abu-Soud, Denis L. Rousseau, Paul L. Feldman, and Jianling Wang

- I. Introduction 207
- II. Role of CaM in the Control of Heme Iron Reduction 208
- III. An Additional Role for CaM 209
- IV. Control of Heme Reduction by Substrate and Substrate Analogs 210
- V. NO Feedback Regulation of NOS 211
- References 212

Negative Modulation of Nitric Oxide Synthase by Nitric Oxide and Nitroso Compounds

Jeanette M. Griscavage, Adrian J. Hobbs, and Louis J. Ignarro

- I. Introduction 215
- II. Inhibition of All Isoforms of NOS by NO and Nitroso Compounds 217
 - A. nNOS 217
 - B. eNOS 219
 - C. iNOS 219

- III. Antagonism of Endothelium-Dependent Relaxation by NO and NO Donor Drugs 222
- IV. Modulation of Endothelium-Dependent Vasodilation by S-Nitrosothiols *in Vivo* 224
- V. Mechanism of Inhibition of Purified nNOS by NO 227
- VI. Summary and Conclusions 230
- References 232

Regulation of Nitric Oxide Synthase: Role of Oxygen Radicals and Cations in Nitric Oxide Formation

Chandra K. Mittal and Chander S. Mehta

- I. Introduction 235
- II. Role of Oxygen Radicals in the Formation of NO and cGMP 236
 - A. Involvement of Superoxide Anion in the Enzymatic Conversion of L-Arginine to NO 236
 - B. cGMP: A Target for Endogenous NO and Oxygen Radicals 241
- III. Calcium-Dependent Modulation of NO Formation 242
 - A. Requirement of Calcium Ion for NO Formation 242
 - B. Calcium-Dependent Inhibition of NO Formation 243
- IV. Effect of Environmental Toxicants on NO Formation 245
- V. Conclusion 247
- References 248

Why Tetrahydrobiopterin?

Bernd Mayer and Ernst R. Werner

- I. Introduction 251
- II. Effects of H₄Biopterin on NOS Activity 252
- III. Effects of H₄Biopterin on NOS Conformation 253
- IV. H₄Biopterin-Induced Oxidation of NO 254
- V. Why H₄Biopterin? 257
- References 259

Nitric Oxide and cGMP Signaling

Lee J. McDonald and Ferid Murad

- I. Introduction 263
- II. NO 264
 - A. NOSs 264

S-Nitrosothiols: Chemistry, Biochemistry, and Biological Actions

Gilbert R. Upchurch, Jr., George N. Welch, and Joseph Loscalzo

- I. Introduction 343
- II. EDRF, Nitric Oxide, and S-Nitrosothiols 343
- III. RSNOs in Biological Systems 345
- IV. S-Nitrosoproteins: Functional Effects of Posttranslational Nitrosation 346
- V. Conclusions 347
- References 348

Glyceraldehyde-3-Phosphate Dehydrogenase: A Target for Nitric Oxide Signaling

Bernhard Brüne and Eduardo G. Lapetina

- I. Introduction 351
- II. Initial NAD⁺-Dependent Protein Modification of a 39-kDa Protein 353
- III. NO-Stimulated NAD⁺-Dependent Modification of GAPDH 353
- IV. Current Understanding of NO-Stimulated GAPDH Modification 355
- References 358

Nitric Oxide Donors: Biochemical Pharmacology and Therapeutics

John Anthony Bauer, Brian P. Booth, and Ho-Leung Fung

- I. Biochemical Pharmacology of NO Donors: How and Where Do They Generate NO? 362
 - A. Organic Nitrates 362
 - B. Organic Nitrites 367
 - C. Sodium Nitroprusside 367
 - D. Sydononimines 368
 - E. S-Nitrosothiols 368
 - F. Nucleophile-NO Adducts 369
 - G. Conclusions 369
- II. Therapeutic Aspects of NO Donors 369
 - A. Systemic Hemodynamic Actions 369
 - B. Other Therapeutic Applications 372
 - C. Local and Cellular Actions 373

D. Pharmacological Tolerance	374
III. Summary	376
References	376

Nitric Oxide Donors: A Continuing Opportunity in Drug Design

Stephen R. Hanson, Thomas C. Hutsell, Larry K. Keefer, Daniel L. Mooradian, and Daniel J. Smith

I. Introduction	383
II. Goal: Reducing Restenosis Risk	385
A. Stenosis and Angioplasty	385
B. What Is Restenosis?	385
C. Experimental Challenge 1	386
D. Caveats	389
E. Platelet Studies in the Baboon	390
F. Experimental Challenge 2	391
G. Experimental Challenge 3	393
III. Artificial Blood Vessels	395
IV. Summary and Significance	396
References	396

Nitric Oxide and Peripheral Adrenergic Neuromodulation

Roberto Levi, Kwan Ha Park, Michiaki Imamura, Nahid Seyedi, and Harry M. Lander

I. Introduction	399
II. Materials and Methods	400
A. Mesenteric Arterial Bed	400
B. Isolated Hearts	401
C. Ischemia/Reperfusion Experiments	401
D. NE Assay	402
E. NE Release from Cardiac Synaptosomes	402
F. Drugs	402
G. Statistics	402
III. Results and Discussion	402
IV. Conclusions	411
References	411

A Study on Tumor Necrosis Factor, Tumor Necrosis Factor Receptors, and Nitric Oxide in Human Fetal Glial Cultures

Barbara A. St. Pierre, Douglas A. Granger, Joyce L. Wong, and Jean E. Merrill

- I. Introduction 415
 - A. Infections 416
 - B. MS 417
- II. NO Production by Human M ϕ and Glia 418
 - A. Monocytes/M ϕ 418
 - B. Glia 419
 - C. Conclusions 420
- III. TNF Production, Effects, and Modulation 421
 - A. TNF Production by Human Glia 421
 - B. TNF Effects on Human Glia 421
 - C. TNF Modulation by Pentoxifylline 422
- IV. TNF-Rs 422
 - A. Structure, Function, and Interactions 422
 - B. Modulation of TNF-Rs 423
 - C. TNF-R Shedding 426
 - D. Conclusions 427
- V. Astrocyte TNF-Rs, TNF, and NO 427
 - A. TNF-R Expression and Functions 427
 - B. TNF-R Modulation 428
 - C. TNF-Rs, TNF, and NO 431
- VI. Potential Roles of TNF-Rs in Association with Astrocyte TNF and NO Production 431
- VII. Conclusions and Recommendations for Future Studies 432
- References 433

Inhaled Nitric Oxide, Clinical Rationale and Applications

Claes G. Frostell and Warren M. Zapol

- I. Background 439
- II. Animal Studies 440
 - A. Administration of Exogenous NO 440
- III. Clinical Studies 442
- IV. Delivery and Monitoring 445
 - A. NO Delivery Systems 445
 - B. Monitoring 446
- V. Adverse Effects of Inhaled NO 447
 - A. Formation of Methemoglobin and Effects on NO on Red Blood Cells 447

- B. Formation of NO_2 448
- C. Interaction with Coagulation 448
- D. S-Nitrosylation and More 449
- E. Mutagenicity 449
- F. Withdrawal Reactions 449
- VI. Summary and Future 450
- References 450

Inhaled Nitric Oxide Therapy of Pulmonary Hypertension and Respiratory Failure in Premature and Term Neonates

Steven H. Abman and John P. Kinsella

- I. Introduction 457
- II. NO in the Perinatal Pulmonary Circulation: Experimental Aspects 458
- III. Role of Inhaled NO Therapy in the Management of Severe PPHN 463
- IV. Role of Inhaled NO Therapy of Premature Neonates with Severe Respiratory Failure 467
- V. Conclusions 469
- References 470

Clinical Applications of Inhaled Nitric Oxide in Children with Pulmonary Hypertension

David L. Wessel and Ian Adata

- I. Pulmonary Hypertension and Congenital Heart Disease 476
- II. Nitric Oxide and Pulmonary Circulation 476
- III. Clinical Investigation of Inhaled Nitric Oxide 477
- IV. Endothelial Cell Function and Cardiopulmonary Bypass 479
- V. Neonate with Congenital Heart Disease 483
- VI. Treatment of Transient Graft Dysfunction Following Lung Transplantation 486
- VII. Assessment of Pulmonary Vascular Reactivity prior to Cardiac or Cardiopulmonary Transplantation 489
- VIII. Congenital Mitral Stenosis 493
- IX. Single-Ventricle Lesions 494
- X. Delivery and Monitoring Considerations 496

XI. Summary	497
References	498

Index	505
-------	-----

Contents of Previous Volumes	517
------------------------------	-----